ARTICLE | Clinical News
Cabaletta regulatory update
May 4, 2015 7:00 AM UTC
FDA granted Fast Track designation to Cabaletta from BioBlast to treat oculopharyngeal muscular dystrophy (OPMD). The compound is in the Phase II/III HOPE trial for OPMD, for which it has Orphan Drug ...